<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>BioMed Central</PublisherName>
    <PublisherLocation>London</PublisherLocation>
    <PublisherImprintName>BioMed Central</PublisherImprintName>
  </PublisherInfo>
  <Journal OutputMedium="Online">
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>13578</JournalID>
      <JournalElectronicISSN>2045-3701</JournalElectronicISSN>
      <JournalTitle>Cell &amp; Bioscience</JournalTitle>
      <JournalAbbreviatedTitle>Cell Biosci</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="SCL" Type="Primary">Life Sciences</JournalSubject>
        <JournalSubject Code="SCL16008" Priority="1" Type="Secondary">Cell Biology</JournalSubject>
        <JournalSubject Code="SCL23004" Priority="2" Type="Secondary">Microbiology</JournalSubject>
        <JournalSubject Code="SCL16010" Priority="3" Type="Secondary">Stem Cells</JournalSubject>
        <JournalSubject Code="SCL25066" Priority="4" Type="Secondary">Neurobiology</JournalSubject>
        <JournalSubject Code="SCL1403X" Priority="5" Type="Secondary">Proteomics</JournalSubject>
        <SubjectCollection Code="Biomedical and Life Sciences">SC3</SubjectCollection>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume OutputMedium="Online">
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>6</VolumeIDStart>
        <VolumeIDEnd>6</VolumeIDEnd>
        <VolumeIssueCount>1</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular" OutputMedium="Online">
        <IssueInfo IssueType="Regular" TocLevels="0">
          <IssueIDStart>1</IssueIDStart>
          <IssueIDEnd>1</IssueIDEnd>
          <IssueArticleCount>0</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2016</Year>
              <Month>12</Month>
            </CoverDate>
            <PricelistYear>2016</PricelistYear>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>The Author(s)</CopyrightHolderName>
            <CopyrightYear>2016</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="s13578-016-0106-6" OutputMedium="Online">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>106</ArticleID>
            <ArticleDOI>10.1186/s13578-016-0106-6</ArticleDOI>
            <ArticleCitationID>40</ArticleCitationID>
            <ArticleSequenceNumber>40</ArticleSequenceNumber>
            <ArticleTitle Language="En" OutputMedium="All">Pituitary adenylate cyclase-activating polypeptide expression in peripheral blood mononuclear cells of migraineurs</ArticleTitle>
            <ArticleCategory>Research</ArticleCategory>
            <ArticleFirstPage>1</ArticleFirstPage>
            <ArticleLastPage>6</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2016</Year>
                <Month>6</Month>
                <Day>1</Day>
              </RegistrationDate>
              <Received>
                <Year>2016</Year>
                <Month>3</Month>
                <Day>25</Day>
              </Received>
              <Accepted>
                <Year>2016</Year>
                <Month>6</Month>
                <Day>2</Day>
              </Accepted>
              <OnlineDate>
                <Year>2016</Year>
                <Month>6</Month>
                <Day>10</Day>
              </OnlineDate>
            </ArticleHistory>
            <ArticleFundingInformation>
              <Fund>
                <FunderName FundRefID="http://dx.doi.org/10.13039/501100001809">National Natural Science Foundation of China</FunderName>
                <GrantNumber GrantRecipient="Au8" Type="FundRef">Nos.81171058, 81471146</GrantNumber>
              </Fund>
              <Fund>
                <FunderName>Capital development Scientific Research in China</FunderName>
                <GrantNumber GrantRecipient="Au8" Type="FundRef">Noas2011-5001-04,2014-405013</GrantNumber>
              </Fund>
            </ArticleFundingInformation>
            <ArticleCopyright>
              <CopyrightHolderName>The Author(s)</CopyrightHolderName>
              <CopyrightYear>2016</CopyrightYear>
              <License SubType="CC BY + CC0" Type="OpenAccess" Version="4.0">
                <SimplePara>
                           <Emphasis Type="Bold">Open Access</Emphasis>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ExternalRef>
                    <RefSource>http://creativecommons.org/licenses/by/4.0/</RefSource>
                    <RefTarget Address="http://creativecommons.org/licenses/by/4.0/" TargetType="URL"/>
                  </ExternalRef>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ExternalRef>
                    <RefSource>http://creativecommons.org/publicdomain/zero/1.0/</RefSource>
                    <RefTarget Address="http://creativecommons.org/publicdomain/zero/1.0/" TargetType="URL"/>
                  </ExternalRef>) applies to the data made available in this article, unless otherwise stated.</SimplePara>
              </License>
            </ArticleCopyright>
            <ArticleGrants Type="OpenChoice">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="OpenAccess"/>
              <BodyHTMLGrant Grant="OpenAccess"/>
              <BibliographyGrant Grant="OpenAccess"/>
              <ESMGrant Grant="OpenAccess"/>
            </ArticleGrants>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1" ID="Au1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Lei</GivenName>
                  <FamilyName>Hou</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>houlei_sz@126.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff1" ID="Au2">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Dongjun</GivenName>
                  <FamilyName>Wan</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>wandongjun2006@163.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff1" ID="Au3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Zhao</GivenName>
                  <FamilyName>Dong</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>18910685535@126.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff1" ID="Au4">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Wenjing</GivenName>
                  <FamilyName>Tang</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>tangwj592.student@sina.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff1" ID="Au5">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Xun</GivenName>
                  <FamilyName>Han</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>cornxun218@163.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff2" ID="Au6">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Li</GivenName>
                  <FamilyName>Li</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>lili_1982@126.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff1" ID="Au7">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Fei</GivenName>
                  <FamilyName>Yang</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>yangfeiyanbian@163.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1" ID="Au8">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Shengyuan</GivenName>
                  <FamilyName>Yu</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>yusy1963@126.com</Email>
                </Contact>
              </Author>
              <Affiliation ID="Aff1">
                <OrgDivision>International Headache Center, Department of Neurology</OrgDivision>
                <OrgName>Chinese PLA General Hospital</OrgName>
                <OrgAddress>
                  <Street>Fuxing Road 28, Haidian District</Street>
                  <City>Beijing</City>
                  <Postcode>100853</Postcode>
                  <Country Code="CN">China</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff2">
                <OrgDivision>Department of Neurology</OrgDivision>
                <OrgName>General Hospital of Jincheng Anthracite Coal Ming Group</OrgName>
                <OrgAddress>
                  <City>Jincheng</City>
                  <Postcode>048000</Postcode>
                  <State>Shanxi Province</State>
                  <Country Code="CN">China</Country>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En" OutputMedium="All">
              <Heading>Abstract</Heading>
              <AbstractSection ID="ASec1">
                <Heading>Background</Heading>
                <Para ID="Par1">Pituitary adenylate cyclase-activating polypeptide (PACAP) plays several important roles in vasodilation, neurotransmission, neuromodulation and neurotrophy, as well as activation of the trigeminovascular system. The aim of the present study was to explore the relationship between altered PACAP levels in peripheral blood and different types of headache.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec2">
                <Heading>Methods</Heading>
                <Para ID="Par2">The present study enrolled 101 outpatients with headache and 35 healthy control volunteers. Blood samples were collected from the cubital vein and peripheral blood mononuclear cells (PBMCs) were separated. Total mRNA in the PBMCs was extracted and the expression of PACAP mRNA was analyzed by quantitative-polymerase chain reaction (Q-PCR).</Para>
              </AbstractSection>
              <AbstractSection ID="ASec3">
                <Heading>Results</Heading>
                <Para ID="Par3">There was a significant decrease in PACAP mRNA expression in the PBMCs of the migraine (M) group relative to the healthy control group. However, there were no significant differences in PACAP mRNA expression between the control group and tension-type headache (TTH), cluster headache (CH), or medication overuse headache (MOH) groups.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec4">
                <Heading>Conclusion</Heading>
                <Para ID="Par4">The PBMC levels of patients with migraine, but not other commonly seen headache types, exhibited a significant reduction in PACAP mRNA expression compared with healthy control subjects.</Para>
              </AbstractSection>
            </Abstract>
            <KeywordGroup Language="En" OutputMedium="All">
              <Heading>Keywords</Heading>
              <Keyword>PACAP</Keyword>
              <Keyword>mRNA expression</Keyword>
              <Keyword>Headache</Keyword>
              <Keyword>Migraine</Keyword>
            </KeywordGroup>
          </ArticleHeader>
          <Body>
            <Section1 ID="Sec1" Type="Introduction">
              <Heading>Background</Heading>
              <Para ID="Par5">Headache can be classified as primary and secondary disorder. The latter was usually caused by another disease, trauma or any certain factors such as medication overuse, tumors or inflammation, while the primary headache was independent [<CitationRef CitationID="CR1">1</CitationRef>]. Approximately 90 % of all headaches are primary, and the most common subtypes are migraine (M), tension-type headache (TTH), and cluster headache (CH) [<CitationRef CitationID="CR1">1</CitationRef>–<CitationRef CitationID="CR3">3</CitationRef>]. The pathophysiology of headache includes traction to or irritation of the meninges and blood vessels, because the brain itself is not sensitive to pain due to its lack of nociceptors [<CitationRef CitationID="CR4">4</CitationRef>]. These receptors, which are located at the extracranial arteries, middle meningeal artery, large veins, and cranial or spinal nerves, send projections up the length of the nerve fiber to nerve cells in the brain and signal that a part of the body hurts [<CitationRef CitationID="CR5">5</CitationRef>].</Para>
              <Para ID="Par6">Pituitary adenylate cyclase-activating polypeptide (PACAP) is a member of the vasoactive intestinal peptide (VIP)/secretin/glucagon peptide family, which is widely expressed in humans in the central nervous system (CNS), endocrine glands, and peripheral organs [<CitationRef CitationID="CR6">6</CitationRef>]. Therefore, PACAP functions as a pleiotropic peptide that influences neurotransmission, neuromodulation, and neurotropic actions in the CNS, vessel dilation and regulatory mechanisms in the gastrointestinal, cardiovascular, reproductive, and respiratory systems, and anti-inflammatory activity in the immune system [<CitationRef CitationID="CR7">7</CitationRef>–<CitationRef CitationID="CR9">9</CitationRef>]. Moreover, recent studies have demonstrated an important role of PACAP in nociceptive processes [<CitationRef CitationID="CR10">10</CitationRef>–<CitationRef CitationID="CR12">12</CitationRef>], identified PACAP in the trigeminal system [<CitationRef CitationID="CR12">12</CitationRef>], and observed the co-localization of nociceptors and PACAP [<CitationRef CitationID="CR13">13</CitationRef>, <CitationRef CitationID="CR14">14</CitationRef>]. Additionally, Schytz et al. [<CitationRef CitationID="CR15">15</CitationRef>] demonstrated that infusion of PACAP causes headache and vasodilatation in both healthy subjects and migraine patients. Taken together, these findings indicate that PACAP is involved in the pathogenesis of headache, but the exact roles it plays in different types of headache remain unclear.</Para>
              <Para ID="Par7">Thus, the present study measured PACAP mRNA expression in peripheral blood mononuclear cells (PBMCs) of headache patients and healthy controls, and aimed to determine the relationships between altered PACAP levels in peripheral blood and different types of headache.</Para>
            </Section1>
            <Section1 ID="Sec2" Type="MaterialsAndMethods">
              <Heading>Methods</Heading>
              <Section2 ID="Sec3">
                <Heading>Participants</Heading>
                <Para ID="Par8">The present study assessed 101 outpatients suffering from headache that visited the International Headache Center in the Department of Neurology at Chinese People’s Liberation Army (PLA) General Hospital from April 2014 to February 2015, and 32 healthy people were recruited as a control group. Patients were selected in accordance with the criteria of the International Classification of Headache Disorders, third edition, beta version (ICHD-3 beta), and were categorized as follows: migraine (M, n = 43), tension-type headache (TTH, n = 23), cluster headache (CH, n = 13), and medication overuse headache (MOH, n = 22). The study groups were age-matched and the demographic and clinical characteristics of both patient and control populations were summarized in Table <InternalRef RefID="Tab1">1</InternalRef>. A detailed questionnaire and examination were used to distinguish the type of headache in each patient, and any subjects (patients or controls) who displayed any other significant or serious disorders were excluded from the study. The study was approved by the Ethics Committee of the PLA General Hospital. All study participants signed an informed consent form, and all procedures were conducted in accordance with the Declaration of Helsinki.<Table Float="Yes" ID="Tab1">
                    <Caption Language="En">
                      <CaptionNumber>Table 1</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>The demographic characteristics comparisons between different types of headaches and healthy control group</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <tgroup cols="6">
                      <colspec align="left" colname="c1" colnum="1"/>
                      <colspec align="left" colname="c2" colnum="2"/>
                      <colspec align="left" colname="c3" colnum="3"/>
                      <colspec align="left" colname="c4" colnum="4"/>
                      <colspec align="left" colname="c5" colnum="5"/>
                      <colspec align="left" colname="c6" colnum="6"/>
                      <thead>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara>Variable</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>Healthy control</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>M</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>TTH</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>CH</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>MOH</SimplePara>
                          </entry>
                        </row>
                      </thead>
                      <tbody>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara>Total</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>32</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>43</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>23</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>13</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>22</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara>Male</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>14 (43.7 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>15 (34.9 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>7 (30.4 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>11 (84.6 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>3 (13.6 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara>Female</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>18 (56.3 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>28 (65.1 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>16 (69.6 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>2 (15.4 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>19 (86.4 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara>Age</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>35.46 ± 8.49</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>35.21 ± 10.44</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>45.17 ± 10.88</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>34.69 ± 10.12</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>46.18 ± 9.60</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> &lt;30</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>9 (28.1 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>14 (32.6 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>2 (8.7 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>6 (46.2 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>1 (4.5 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> 30–40</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>15 (46.9 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>12 (27.9 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>6 (26.1 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>4 (30.8 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>5 (22.7 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> &gt;40</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>8 (25 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>17 (39.5 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>15 (65.2 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>3 (23.1 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>16 (72.7 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" nameend="c6" namest="c1">
                            <SimplePara>Education</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> Junior colleague or lower</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>12 (37.5 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>26 (60.4 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>17 (74.0 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>9 (69.2 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>17 (77.3 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> University or above</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>20 (62.5 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>17 (39.6 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>6 (26.0 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>4 (30.8 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>5 (22.7 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" nameend="c6" namest="c1">
                            <SimplePara>BMI</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> Underweight (&lt;18.5)</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>3 (9.4 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>3 (7.0 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>0</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>1 (7.7 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>2 (9.1 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> Normal weight (18.5 to &lt;23)</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>23 (71.9 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>24 (55.8 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>10 (43.5 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>5 (38.5 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>8 (36.4 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> Overweight (23 to &lt;25)</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>4 (12.5 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>6 (14.0 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>5 (21.7 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>2 (15.4 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>6 (27.3 %)</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> Obese (≥25)</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>2 (6.2 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>10 (23.3 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>8 (34.8 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c5">
                            <SimplePara>5 (38.5 %)</SimplePara>
                          </entry>
                          <entry align="left" colname="c6">
                            <SimplePara>6 (27.3 %)</SimplePara>
                          </entry>
                        </row>
                      </tbody>
                    </tgroup>
                  </Table>
                        </Para>
              </Section2>
              <Section2 ID="Sec4">
                <Heading>Sample collection and preparation</Heading>
                <Para ID="Par9">There were no restrictions placed on the subjects regarding food or drink intake. All study subjects provided blood samples (3 ml per subject). Each sample was drawn from the cubital vein, collected in an ice-cold glass tube containing the anticoagulant ethylenediaminetetraacetic acid (EDTA), and centrifuged within 1 h at 4000 rpm for 5 min at 4 °C. After centrifugation, PBMCs in the cell pellets were isolated using Ficoll-Paque PLUS (GE Healthcare; Piscataway, NJ, USA) and stored at −80 °C until the further use.</Para>
              </Section2>
              <Section2 ID="Sec5">
                <Heading>RNA extraction and reverse transcription</Heading>
                <Para ID="Par10">Using TRIpure LS reagent (Bioteke; Beijing, China), the total RNA was extracted according to the manufacturer’s protocol. Briefly, 1 ml of fresh blood was lysed with 3 ml TRIpure LS reagent. RNA was separated using chloroform, precipitated with isopropanol, and then washed with 70 % ethanol. Next, the RNA pellet was air-dried and dissolved in RNase-free water. To remove genomic DNA contamination, total RNA was incubated with RNase-free DNase, and then the purified RNA was quantified with a spectrophotometer and stored at −80 °C. First-strand cDNA synthesis was performed for each RNA sample using the Sensiscript RT kit with random hexamers used to prime cDNA synthesis.</Para>
              </Section2>
              <Section2 ID="Sec6">
                <Heading>Quantitative-polymerase chain reaction (Q-PCR)</Heading>
                <Para ID="Par11">Primers were designed with Primer Premier 5.0 software and synthesized by the CapitalBio Corporation (Beijing, China) as follows: GAPDH: sense 5′-TGTTGCCATCAATGACCCCTT-3′; anti-sense 5′-CTCCACGACGTACTCAGCG-3′;PACAP: sense 5′-TGTTCCCGTGGCTAGTTGC-3′; anti-sense 5′-ATCTGCTTCAGTTTAGTAAGGCTCT-3′.</Para>
                <Para ID="Par12">The mRNA expression analyses of PACAP and phosphoglyceraldehyde dehydrogenase (GAPDH) were performed by real-time PCR with SYBR Green Master Mix (Applied Biosystems; Foster City, USA). The thermocycler conditions consisted of an initial holding at 50 °C for 2 min and then at 95 °C for 10 min; this was followed by a two-step PCR program at 95 °C for 15 s and 60 °C for 60 s for 40 cycles. All data were collected and quantitatively analyzed on an ABI Prism 7500 Sequence Detection System (Applied Biosystems). The GAPDH gene served as an endogenous control to normalize for differences in the amount of total RNA in each sample. All quantities are expressed as the number of fold increase relative to that of GAPDH.</Para>
              </Section2>
              <Section2 ID="Sec7">
                <Heading>Statistical analysis</Heading>
                <Para ID="Par13">All data were processed using SPSS 19.0. Continuous variables are presented as the mean ± standard deviation, and categorical variables as frequency counts and percentages. The normality of the data was tested with the Shapiro–Wilk test. Additionally, a correlation analysis was performed using a Student’s unpaired t test and a single-factor analysis of variance (ANOVA) to determine whether any relationships existed between the patient characteristics and PACAP levels. Finally, the levels of PACAP were compared between the headache groups and healthy controls with a single-factor analysis of variance (ANOVA). A p value &lt;0.05 was considered to indicate statistical significance.</Para>
              </Section2>
            </Section1>
            <Section1 ID="Sec8" Type="Results">
              <Heading>Results</Heading>
              <Section2 ID="Sec9">
                <Heading>The demographic characteristics comparisons between different types of headaches and healthy control group</Heading>
                <Para ID="Par14">Comparison of the demographic data among the different headache groups and the control group is shown in Table <InternalRef RefID="Tab1">1</InternalRef>. The ages of the 101 headache patients ranged from 14 to 69 years (M: 14–58 years, 35.21 ± 10.44 years; TTH: 24–69 years, 45.17 ± 10.88 years; CH: 25–55 years, 34.69 ± 10.12 years; MOH: 23–63 years, 46.18 ± 9.60 years), and the ages of the 32 control subjects ranged from 20 to 51 years (35.46 ± 8.49 years). Patients were also categorized into groups based on their body mass index (BMI; underweight, normal weight, overweight, and obese) and level of education (junior colleague or lower and university or above). A correlation analysis revealed no significant correlation between PACAP mRNA levels and any patient characteristics, including age, gender, education, or BMI (p &gt; 0.05) (Table <InternalRef RefID="Tab2">2</InternalRef>).<Table Float="Yes" ID="Tab2">
                    <Caption Language="En">
                      <CaptionNumber>Table 2</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>PACAP mRNA levels and patient characteristics</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <tgroup cols="4">
                      <colspec align="left" colname="c1" colnum="1"/>
                      <colspec align="left" colname="c2" colnum="2"/>
                      <colspec align="left" colname="c3" colnum="3"/>
                      <colspec align="left" colname="c4" colnum="4"/>
                      <thead>
                        <row>
                          <entry align="left" colname="c1"/>
                          <entry align="left" colname="c2">
                            <SimplePara>n</SimplePara>
                          </entry>
                          <entry align="left" colname="c3">
                            <SimplePara>2<Superscript>−△Ct</Superscript> (×10<Superscript>−3</Superscript>)</SimplePara>
                          </entry>
                          <entry align="left" colname="c4">
                            <SimplePara>p value</SimplePara>
                          </entry>
                        </row>
                      </thead>
                      <tbody>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara>Gender</SimplePara>
                          </entry>
                          <entry align="left" colname="c2"/>
                          <entry align="left" colname="c3"/>
                          <entry align="left" colname="c4">
                            <SimplePara>&gt;0.05</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> Male</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>50</SimplePara>
                          </entry>
                          <entry align="char" char="±" colname="c3">
                            <SimplePara>0.5333 ± 0.0829</SimplePara>
                          </entry>
                          <entry align="left" colname="c4"/>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> Female</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>83</SimplePara>
                          </entry>
                          <entry align="char" char="±" colname="c3">
                            <SimplePara>0.4907 ± 0.0676</SimplePara>
                          </entry>
                          <entry align="left" colname="c4"/>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara>Age</SimplePara>
                          </entry>
                          <entry align="left" colname="c2"/>
                          <entry align="char" char="±" colname="c3"/>
                          <entry align="left" colname="c4">
                            <SimplePara>&gt;0.05</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> &lt;30</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>32</SimplePara>
                          </entry>
                          <entry align="char" char="±" colname="c3">
                            <SimplePara>0.4850 ± 0.0920 </SimplePara>
                          </entry>
                          <entry align="left" colname="c4"/>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> 30–40</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>42</SimplePara>
                          </entry>
                          <entry align="char" char="±" colname="c3">
                            <SimplePara>0.3954 ± 0.0601</SimplePara>
                          </entry>
                          <entry align="left" colname="c4"/>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> &gt;40</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>59</SimplePara>
                          </entry>
                          <entry align="char" char="±" colname="c3">
                            <SimplePara>0.6320 ± 0.0962</SimplePara>
                          </entry>
                          <entry align="left" colname="c4"/>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara>Education</SimplePara>
                          </entry>
                          <entry align="left" colname="c2"/>
                          <entry align="char" char="±" colname="c3"/>
                          <entry align="left" colname="c4">
                            <SimplePara>&gt;0.05</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> Junior colleague or lower</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>81</SimplePara>
                          </entry>
                          <entry align="char" char="±" colname="c3">
                            <SimplePara>0.4558 ± 0.0528</SimplePara>
                          </entry>
                          <entry align="left" colname="c4"/>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> University or above</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>52</SimplePara>
                          </entry>
                          <entry align="char" char="±" colname="c3">
                            <SimplePara>0.6146 ± 0.1042</SimplePara>
                          </entry>
                          <entry align="left" colname="c4"/>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara>BMI</SimplePara>
                          </entry>
                          <entry align="left" colname="c2"/>
                          <entry align="char" char="±" colname="c3"/>
                          <entry align="left" colname="c4">
                            <SimplePara>&gt;0.05</SimplePara>
                          </entry>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> Underweight (&lt;18.5)</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>9</SimplePara>
                          </entry>
                          <entry align="char" char="±" colname="c3">
                            <SimplePara>0.4677 ± 0.2037</SimplePara>
                          </entry>
                          <entry align="left" colname="c4"/>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> Normal weight (18.5 to &lt;23)</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>70</SimplePara>
                          </entry>
                          <entry align="char" char="±" colname="c3">
                            <SimplePara>0.5166 ± 0.0675</SimplePara>
                          </entry>
                          <entry align="left" colname="c4"/>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> Overweight (23 to &lt;25)</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>23</SimplePara>
                          </entry>
                          <entry align="char" char="±" colname="c3">
                            <SimplePara>0.4123 ± 0.1104</SimplePara>
                          </entry>
                          <entry align="left" colname="c4"/>
                        </row>
                        <row>
                          <entry align="left" colname="c1">
                            <SimplePara> Obese (≥25)</SimplePara>
                          </entry>
                          <entry align="left" colname="c2">
                            <SimplePara>31</SimplePara>
                          </entry>
                          <entry align="char" char="±" colname="c3">
                            <SimplePara>0.4123 ± 0.1104</SimplePara>
                          </entry>
                          <entry align="left" colname="c4"/>
                        </row>
                      </tbody>
                    </tgroup>
                  </Table>
                        </Para>
              </Section2>
              <Section2 ID="Sec10">
                <Heading>The PACAP expression in the PBMCs of headache patients and the healthy controls</Heading>
                <Para ID="Par15">To determine the expression of PACAP mRNA in the PBMCs of headache patients, PBMCs were isolated and then evaluated using Q-PCR. To examine whether the level of PACAP mRNA expression in the PBMCs correlated with headache, the data for M, TTH, CH and MOH groups were compared with the healthy control group respectively. Figure <InternalRef RefID="Fig1">1</InternalRef> shows that compared with control groups (n = 32; 0.6155 ± 0.1050), there was an obvious decrease in the level of PACAP expression in the PBMCs of the M group (n = 43; 0.3693 ± 0.0562; p = 0.0304). However, no significant difference was observed between the TTH, CH, MOH groups and control groups (p &gt; 0.05) (Fig. <InternalRef RefID="Fig2">2</InternalRef>), which suggested relative specificity for migraine.<Figure Category="Standard" Float="Yes" ID="Fig1">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 1</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>PACAP expression in migraine groups and controls. Comparison of −ΔCt of PACAP mRNA expression between migraine patients and the control groups showed that control group had higher −ΔCt than the patient group (controls: n = 35; mean −ΔCt: 0.6155 ± 0.1050; migraineurs: n = 43; 0.3693 ± 0.0562; p = 0.0304)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO1">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/13578_2016_106_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                           <Figure Category="Standard" Float="Yes" ID="Fig2">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 2</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>PACAP expression in CH, TTH, MOH groups and controls. Comparison of −ΔCt of PACAP mRNA expression between TTH, CH and MOH patients and the control groups showed no significant differences between the patient groups and controls.(controls: mean −ΔCt: 0.6155 ± 0.1050; TTH: 0.4683 ± 0.1448, p = 0.4035; CH: 0.4092 ± 0.1099, p = 0.2570; MOH: 0.5371 ± 0.1785, p = 0.8014)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO2">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/13578_2016_106_Fig2_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
              </Section2>
              <Section2 ID="Sec11">
                <Heading>The PACAP expression in the PBMCs of migraineurs</Heading>
                <Para ID="Par16">The results above suggested the PACAP expression in the PBMCs has correlation with migraine, but not with TTH, CH and MOH. Therefore, to investigate the relationship between the PACAP expression and migraineurs’ characteristics, the migraine group was subdivided into male and female groups, interictal and attack groups, and with aura (MA) and without aura (MO) groups, but no significant differences in PACAP levels were observed (p &gt; 0.05) (Figs. <InternalRef RefID="Fig3">3</InternalRef>, <InternalRef RefID="Fig4">4</InternalRef>, <InternalRef RefID="Fig5">5</InternalRef>). But Fig. <InternalRef RefID="Fig5">5</InternalRef> presents an uptrend of PACAP expression during migraine attack compared with interictal (0.3994 ± 0.3673 vs 0.2923 ± 0.3560).<Figure Category="Standard" Float="Yes" ID="Fig3">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 3</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>PACAP expression in female and male migraineurs. No significant differences of PACAP expression in PBMCs of patients were observed between male and female migraineurs. (female: mean −ΔCt 0.4003 ± 0.06623; male: 0.3114 ± 0.1052, p &gt; 0.05)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO3">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/13578_2016_106_Fig3_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure> 
                           <Figure Category="Standard" Float="Yes" ID="Fig4">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 4</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>PACAP expression in migraine with (MA) and without aura (MO). No significant differences of PACAP expression in PBMCs of patients were observed between MA and MO groups. (MO: mean −ΔCt 0.3843 ± 0.06496; MA: 0.3125 ± 0.1146, p &gt; 0.05)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO4">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/13578_2016_106_Fig4_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure> 
                           <Figure Category="Standard" Float="Yes" ID="Fig5">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 5</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>PACAP expression in migraine attack and interictal groups. The results presents an uptrend of PACAP expression during migraine attack compared with interictal (attack groups: mean −ΔCt 0.3994 ± 0.3673; interictal groups: 0.2923 ± 0.3560, p &gt; 0.05)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO5">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/13578_2016_106_Fig5_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
              </Section2>
            </Section1>
            <Section1 ID="Sec12" Type="Discussion">
              <Heading>Discussion</Heading>
              <Para ID="Par17">The present findings identified a relationship between the expression of PACAP mRNA in mononuclear cells derived from the peripheral blood of headache patients and different types of headache. A detailed analysis revealed that the PBMCs of migraineurs exhibited a significantly lower level of PACAP mRNA expression than that of the control group, but there were no significant differences between the control group and TTH, CH, or MOH groups. Moreover, no significant correlation was observed between PACAP expression and age, gender, BMI, or the pain intensity and duration of headache in any headache group. These findings suggest that PACAP may be an effective marker for the identification of migraineurs and that the monitoring of these levels can inform a physician about the progression of migraine.</Para>
              <Para ID="Par18">PACAP is a member of the VIP/secretin/glucagon peptide family encoded by the ADCYAP1 gene and is widely expressed in the CNS and peripheral tissues [<CitationRef CitationID="CR16">16</CitationRef>]. It has been reported that PACAP can induce neurogenic inflammation, neuronal activation and sensitization, and mast cell degranulation, which can all be involved in headache development [<CitationRef CitationID="CR17">17</CitationRef>]. Moreover, a previous study from our research group found that patients suffering from migraine exhibited lower plasma levels of PACAP compared to healthy control donors. Additionally, a negative correlation between interictal PACAP-38-LI and the duration of migraine was recently shown, but no relationships between plasma PACAP levels and gender, age, attack frequency, allodynia, or hormonal changes have been demonstrated [<CitationRef CitationID="CR15">15</CitationRef>]. Furthermore, although in the present study, no significant differences in PACAP expression were found between the control group and TTH, CH, or MOH groups, the PACAP expression in migraineurs was significantly higher than that in the control group, which indicate that PACAP may act as a potential marker highly specific for migraine.</Para>
              <Para ID="Par19">However, which types of cells that act as the major source of or cause the changes in PACAP levels in patients with migraine remain unclear. Migraine has been associated with disordered immune responses [<CitationRef CitationID="CR18">18</CitationRef>] and PACAP protein can be secreted by multiple types of cells, including neurons and immune cells [<CitationRef CitationID="CR6">6</CitationRef>]. Thus, the detection of PACAP expression in immune cells may explain the correlation between immune responses and migraine. Isolation of PBMCs in the present study revealed that migraineurs exhibited a lower level of PACAP mRNA than the healthy controls. This is in accordance with the results of a previous study from our research group which indicated that the level of PACAP mRNA in PBMCs reflects changes in plasma levels of PACAP [<CitationRef CitationID="CR19">19</CitationRef>]. However, in the present study, there was no relationship between the levels of PACAP mRNA in PBMCs and age, gender, BMI, or the pain intensity and duration of migraine. Further investigation is warranted to determine whether other peripheral tissue cells with similar patterns of PACAP expression can be described in the plasma and PBMCs.</Para>
              <Para ID="Par20">The present study also assessed PACAP mRNA expression in the PBMCs of patients suffering from TTH, CH and MOH. In contrast to migraineurs, no significant differences in PACAP mRNA expression were found compared to the healthy control group, indicating that the PACAP mRNA level in PBMCs may be used as a marker for the differential diagnosis of migraine. To date, other than the calcitonin gene-related peptide (CGRP) [<CitationRef CitationID="CR20">20</CitationRef>], no markers has been identified,which could classify the headache into different subtypes.</Para>
              <Para ID="Par21">In the present study, monitoring of PACAP mRNA expression in PBMCs during the progression of M revealed that PACAP levels were higher in the attack stage than the interictal stage. It was previously shown that migraineurs have elevated PACAP levels during the ictal period relative to the attack-free period [<CitationRef CitationID="CR21">21</CitationRef>]. Taken together, these findings suggest that PACAP may be involved in the development of migraine attacks and that the difference between these two stages may be due to different types of PACAP and various levels of protein and mRNA expression. Future studies should include a larger number of patients and perform detailed analyses investigating PACAP protein and mRNA levels simultaneously.</Para>
              <Para ID="Par22">The findings of the present study indicate that PACAP mRNA levels in PBMCs may be used to conduct a differential diagnosis of migraine. Additionally, the changes in PACAP levels in PBMCs may represent a potential mechanism that links immune responses and the CNS.</Para>
            </Section1>
            <Section1 ID="Sec13" Type="Conclusion">
              <Heading>Conclusion</Heading>
              <Para ID="Par23">The PBMC levels of patients with migraine, but not other commonly seen headache types, exhibited a significant reduction in PACAP mRNA expression compared with healthy control subjects. The findings indicate that PACAP mRNA levels in PBMCs may be used to conduct a differential diagnosis of migraine and the changes in PACAP levels in PBMCs may represent a potential mechanism that links immune responses and the CNS.</Para>
            </Section1>
          </Body>
          <BodyRef FileRef="BodyRef/PDF/13578_2016_Article_106.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Acknowledgments>
              <Heading>Authors’ contributions</Heading>
              <SimplePara>LH carried out the molecular genetic studies and drafted the manuscript. DJW carried out the data collection of all participants. ZD and FY carried out the enrollment and blood sample collection of all participants. WJT performed the RNA extraction and PCR tests. LL performed the statistical analysis. SYY conceived of the study and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.</SimplePara>
              <FormalPara ID="FPar1" RenderingStyle="Style1">
                <Heading>Authors’ information</Heading>
                <Para ID="Par24">Shengyuan Yu is the director of the department of Neurology of Chinese PLA General Hospital. LH, DJW, ZD, WJT, XH and FY are doctors in the department of neurology of Chinese PLA General Hospital. All authors hold a doctor’s degree.</Para>
              </FormalPara>
              <FormalPara ID="FPar2" RenderingStyle="Style1">
                <Heading>Acknowledgements</Heading>
                <Para ID="Par25">This research is funded by the National Science Foundation Committee (NSFC) of China (Nos. 81171058, 81471146) and Capital development Scientific Research in China (Nos. 2011-5001-04, 2014-405013).</Para>
              </FormalPara>
              <FormalPara ID="FPar3" RenderingStyle="Style1">
                <Heading>Competing interests</Heading>
                <Para ID="Par26">The authors declare that they have no competing interests.</Para>
              </FormalPara>
            </Acknowledgments>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Olesen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Goadsby</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Steiner</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">The International Classification of Headache Disorders: 2nd edition</ArticleTitle>
                  <JournalTitle>Cephalalgia</JournalTitle>
                  <VolumeID>24</VolumeID>
                  <IssueID>Suppl 1</IssueID>
                  <FirstPage>9</FirstPage>
                  <LastPage>160</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1468-2982.2003.00824.x</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Olesen J, Goadsby P, Steiner T, et al. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(Suppl 1):9–160.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Olesen</FamilyName>
                  </BibAuthorName>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache</ArticleTitle>
                  <JournalTitle>Pharmacol Ther</JournalTitle>
                  <VolumeID>120</VolumeID>
                  <IssueID>2</IssueID>
                  <FirstPage>157</FirstPage>
                  <LastPage>171</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1cXht1Knsb3I</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.pharmthera.2008.08.003</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>18789357</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Olesen J. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther. 2008;120(2):157–71.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <InstitutionalAuthorName>HCCOH Society</InstitutionalAuthorName>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">The International Classification of Headache Disorders, 3rd edition (beta version)</ArticleTitle>
                  <JournalTitle>Cephalalgia</JournalTitle>
                  <VolumeID>33</VolumeID>
                  <FirstPage>629</FirstPage>
                  <LastPage>808</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1177/0333102413485658</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>HCCOH Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AM</Initials>
                    <FamilyName>Strassman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SA</Initials>
                    <FamilyName>Raymond</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Burstein</FamilyName>
                  </BibAuthorName>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Sensitization of meningeal sensory neurons and the origin of headaches</ArticleTitle>
                  <JournalTitle>Nature</JournalTitle>
                  <VolumeID>384</VolumeID>
                  <FirstPage>560</FirstPage>
                  <LastPage>564</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXhtlWh</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/384560a0</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>8955268</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature. 1996;384:560–4.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AE</Initials>
                    <FamilyName>Dubin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Patapoutian</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Nociceptors: the sensors of the pain pathway</ArticleTitle>
                  <JournalTitle>J Clin Invest</JournalTitle>
                  <VolumeID>120</VolumeID>
                  <IssueID>11</IssueID>
                  <FirstPage>3760</FirstPage>
                  <LastPage>3772</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXhsVWgtb3P</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1172/JCI42843</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>21041958</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2964977</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Dubin AE, Patapoutian A. Nociceptors: the sensors of the pain pathway. J Clin Invest. 2010;120(11):3760–72.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Vaudry</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Falluel-Morel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Bourgault</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery</ArticleTitle>
                  <JournalTitle>Pharmacol Rev</JournalTitle>
                  <VolumeID>61</VolumeID>
                  <IssueID>3</IssueID>
                  <FirstPage>283</FirstPage>
                  <LastPage>357</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXhsVWmu7vK</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/pr.109.001370</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>19805477</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009;61(3):283–357.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Peña</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">PACAP modulates the respiratory rhythm generated in the brainstem slice preparation</ArticleTitle>
                  <JournalTitle>Adv Exp Med Biol</JournalTitle>
                  <VolumeID>669</VolumeID>
                  <FirstPage>119</FirstPage>
                  <LastPage>122</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/978-1-4419-5692-7_24</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20217333</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Peña F. PACAP modulates the respiratory rhythm generated in the brainstem slice preparation. Adv Exp Med Biol. 2010;669:119–22.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Yossan-Var</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Catalina</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Lopez</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Pituitary adenylylcyclase-activating polypeptide is an intrinsic regulator of Treg bundance and protects against experimental autoimmune encephalomyelitis</ArticleTitle>
                  <JournalTitle>PNAS</JournalTitle>
                  <VolumeID>106</VolumeID>
                  <IssueID>6</IssueID>
                  <FirstPage>2012</FirstPage>
                  <LastPage>2017</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.0812257106</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Yossan-Var T, Catalina A, Lopez R, et al. Pituitary adenylylcyclase-activating polypeptide is an intrinsic regulator of Treg bundance and protects against experimental autoimmune encephalomyelitis. PNAS. 2009;106(6):2012–7.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Shen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DR</Initials>
                    <FamilyName>Gehlert</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DA</Initials>
                    <FamilyName>Collier</FamilyName>
                  </BibAuthorName>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">Collier. PACAP and PAC1 receptor in brain development and behavior</ArticleTitle>
                  <JournalTitle>Neuropeptides</JournalTitle>
                  <VolumeID>47</VolumeID>
                  <IssueID>6</IssueID>
                  <FirstPage>421</FirstPage>
                  <LastPage>430</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3sXhslKmsbvJ</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.npep.2013.10.005</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24220567</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Shen S, Gehlert DR, Collier DA. Collier. PACAP and PAC1 receptor in brain development and behavior. Neuropeptides. 2013;47(6):421–30.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>KY</Initials>
                    <FamilyName>Chan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Baun</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Vries</FamilyName>
                    <Particle>de</Particle>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2011</Year>
                  <ArticleTitle Language="En">Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery</ArticleTitle>
                  <JournalTitle>Cephalalgia</JournalTitle>
                  <VolumeID>31</VolumeID>
                  <IssueID>2</IssueID>
                  <FirstPage>181</FirstPage>
                  <LastPage>189</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1177/0333102410375624</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20974589</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Chan KY, Baun M, de Vries R, et al. Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. Cephalalgia. 2011;31(2):181–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Sandor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Kormos</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Botz</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Impaired nocifensive behaviours and mechanical hyperalgesia, but enhanced thermal allodynia in pituitary adenylate cyclase-activating polypeptide deficient mice</ArticleTitle>
                  <JournalTitle>Neuropeptides</JournalTitle>
                  <VolumeID>44</VolumeID>
                  <IssueID>5</IssueID>
                  <FirstPage>363</FirstPage>
                  <LastPage>371</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXhtFamsbzM</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.npep.2010.06.004</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20621353</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sandor K, Kormos V, Botz B, et al. Impaired nocifensive behaviours and mechanical hyperalgesia, but enhanced thermal allodynia in pituitary adenylate cyclase-activating polypeptide deficient mice. Neuropeptides. 2010;44(5):363–71.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Markovics</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Kormos</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Gaszner</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol-induced trigeminovascular activation in mice</ArticleTitle>
                  <JournalTitle>Neurobiol Dis</JournalTitle>
                  <VolumeID>45</VolumeID>
                  <IssueID>1</IssueID>
                  <FirstPage>633</FirstPage>
                  <LastPage>644</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3MXhsFGqsbvM</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.nbd.2011.10.010</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>22033344</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Markovics A, Kormos V, Gaszner B, et al. Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol-induced trigeminovascular activation in mice. Neurobiol Dis. 2012;45(1):633–44.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Uddman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Tajti</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Hou</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2</ArticleTitle>
                  <JournalTitle>Cephalalgia</JournalTitle>
                  <VolumeID>22</VolumeID>
                  <IssueID>2</IssueID>
                  <FirstPage>112</FirstPage>
                  <LastPage>116</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD383lsVyjuw%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1046/j.1468-2982.2002.00324.x</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>11972578</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Uddman R, Tajti J, Hou M, et al. Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia. 2002;22(2):112–6.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>FM</Initials>
                    <FamilyName>Baeres</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Moller</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Origin of PACAP-immunoreactive nerve fibers innervating the subarachnoidal blood vessels of the rat brain</ArticleTitle>
                  <JournalTitle>J Cereb Blood Flow Metab</JournalTitle>
                  <VolumeID>24</VolumeID>
                  <IssueID>6</IssueID>
                  <FirstPage>628</FirstPage>
                  <LastPage>635</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15181370</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Baeres FM, Moller M. Origin of PACAP-immunoreactive nerve fibers innervating the subarachnoidal blood vessels of the rat brain. J Cereb Blood Flow Metab. 2004;24(6):628–35.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HW</Initials>
                    <FamilyName>Schytz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Birk</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Wienecke</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">PACAP38 induces migraine-like attacks in patients with migraine without aura</ArticleTitle>
                  <JournalTitle>Brain</JournalTitle>
                  <VolumeID>132</VolumeID>
                  <IssueID>Pt 1</IssueID>
                  <FirstPage>16</FirstPage>
                  <LastPage>25</LastPage>
                  <Occurrence Type="PID">
                    <Handle>19052139</Handle>
                  </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1093/brain/awn307</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Schytz HW, Birk S, Wienecke T, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009;132(Pt 1):16–25.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Miyata</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Arimura</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RR</Initials>
                    <FamilyName>Dahl</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1989</Year>
                  <ArticleTitle Language="En">Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells</ArticleTitle>
                  <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                  <VolumeID>164</VolumeID>
                  <IssueID>1</IssueID>
                  <FirstPage>567</FirstPage>
                  <LastPage>574</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3cXps1Y%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0006-291X(89)91757-9</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>2803320</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Miyata A, Arimura A, Dahl RR, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun. 1989;164(1):567–74.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HW</Initials>
                    <FamilyName>Schytz</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Investigation of carbachol and PACAP38 in a human model of migraine</ArticleTitle>
                  <JournalTitle>Dan Med Bull</JournalTitle>
                  <VolumeID>57</VolumeID>
                  <IssueID>12</IssueID>
                  <FirstPage>B4223</FirstPage>
                  <Occurrence Type="PID">
                    <Handle>21122466</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Schytz HW. Investigation of carbachol and PACAP38 in a human model of migraine. Dan Med Bull. 2010;57(12):B4223.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PP</Initials>
                    <FamilyName>Bruno</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Carpino</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Carpino</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">An overview on immune system and migarine</ArticleTitle>
                  <JournalTitle>Eur Rev Med Pharmacol Sci</JournalTitle>
                  <VolumeID>11</VolumeID>
                  <IssueID>4</IssueID>
                  <FirstPage>245</FirstPage>
                  <LastPage>248</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD2srlvVClsA%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>17876959</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bruno PP, Carpino F, Carpino G, et al. An overview on immune system and migarine. Eur Rev Med Pharmacol Sci. 2007;11(4):245–8.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>X</Initials>
                    <FamilyName>Han</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SY</Initials>
                    <FamilyName>Yu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Hou</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2015</Year>
                  <ArticleTitle Language="En">Interictal plasma pituitary adenylate cyclase-activating polypeptide levels are decreased in migraineurs but remain unchanged in patients with tension-type headache</ArticleTitle>
                  <JournalTitle>Clin Chim Acta</JournalTitle>
                  <VolumeID>450</VolumeID>
                  <FirstPage>151</FirstPage>
                  <LastPage>154</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC2MXhtlygu7%2FK</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.cca.2015.08.017</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>26296898</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Han X, Yu SY, Hou L, et al. Interictal plasma pituitary adenylate cyclase-activating polypeptide levels are decreased in migraineurs but remain unchanged in patients with tension-type headache. Clin Chim Acta. 2015;450:151–4.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Frese</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Schilgen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Edvinsson</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Calcitonin gene-related peptide in cervicogenic headache</ArticleTitle>
                  <JournalTitle>Cephalalgia</JournalTitle>
                  <VolumeID>25</VolumeID>
                  <IssueID>9</IssueID>
                  <FirstPage>700</FirstPage>
                  <LastPage>703</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD2Mvkt1agtg%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1468-2982.2004.00940.x</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>16109051</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Frese A, Schilgen M, Edvinsson L, et al. Calcitonin gene-related peptide in cervicogenic headache. Cephalalgia. 2005;25(9):700–3.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Tuka</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Z</Initials>
                    <FamilyName>Helyes</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Markovics</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients</ArticleTitle>
                  <JournalTitle>Cephalalgia</JournalTitle>
                  <VolumeID>33</VolumeID>
                  <IssueID>13</IssueID>
                  <FirstPage>1085</FirstPage>
                  <LastPage>1095</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1177/0333102413483931</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>23598374</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Tuka B, Helyes Z, Markovics A, et al. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia. 2013;33(13):1085–95.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
